The prevalence of HLA-B27 in the United States: Data from the U.S. National Health and Nutrition Examination Survey, 2009
Arthritis & Rheumatism, 05/03/2012
Reveille JD et al. – The findings provide the first US national prevalence estimates for HLA–B27. A decline in the prevalence of HLA–B27 with age is suggested by these data but must be confirmed by additional studies.
The national prevalence of HLA–B27 was determined as part of the 2009 US National Health and Nutrition Examination Survey (NHANES), a cross–sectional survey monitoring the health and nutritional status of the US civilian, noninstitutionalized population.
DNA polymerase chain reaction analysis was conducted in samples from 2,320 adults ages 20–69 years from this nationally representative sample.
The age–adjusted US prevalence of B27 was 6.1% (95% confidence interval [95% CI] 4.6–8.2).
By race/ethnicity, the prevalence of B27 was 7.5% (95% CI 5.3–10.4) among non–Hispanic whites and 3.5% (95% CI 2.5–4.8) among all other US races/ethnicities combined.
In Mexican Americans, the prevalence was 4.6% (95% CI 3.4–6.1).
The prevalence of B27 could not be reliably estimated for other US racial/ethnic groups because of the low number of B27–positive individuals in those groups.
For adults 50–69 years of age, the prevalence of B27 was 3.6% (95% CI 2.2–5.8), which suggested a decrease in B27 with age.
These prevalence estimates took into account the NHANES survey design and are reviewed with respect to data from the medical literature.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.